• A novel and safe approach for treating cognitive disorders

Our drug projects

GABAA receptor modulating steroid antagonists: our scientific focus

Our lead product candidate, golexanolone, is a novel small molecule GABAA receptor-modulating steroid antagonist in development for the treatment of neurological disorders caused by overactivation of GABA-A receptors by the neurosteroid allopregnanolone.